$0.000001
At close: May 9, 10:17 AM EDT
Comments
Loading...
CaliPharms Analyst Ratings and Price Targets | OTC:KGET | Benzinga
CaliPharms Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for CaliPharms Corp from these most-recent analyst ratings.
Analyst Ratings for CaliPharms
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for CaliPharms (KGET) stock?
There is no price target for CaliPharms
What is the most recent analyst rating for CaliPharms (KGET)?
There is no analyst for CaliPharms
When was the last upgrade for CaliPharms (KGET)?
There is no last upgrade for CaliPharms
When was the last downgrade for CaliPharms (KGET)?
There is no last downgrade for CaliPharms.
When is the next analyst rating going to be posted or updated for CaliPharms (KGET)?
There is no next analyst rating for CaliPharms.
Is the Analyst Rating CaliPharms (KGET) correct?
There is no next analyst rating for CaliPharms.
Browse analyst ratings and price targets on all stocks.
